Several derivatives and analogs of the recently reported antiproliferative and antitumor agent ?ran5-bis(salicylaldoximato)copper(II) (C uSA 02) have been prepared and tested for antiproliferative activity against L1210 leukemia cells in vitro. The salicylaldimine analog of C uSA 02 had a very strong antiproliferative activity, the 2-day IC50 value being lower than 3 ng/ml-The 2,3-dihydroxybenzaldoxime analog was equally active with C uSA 02, while the corre sponding 2,5-dihydroxy derivative had a slightly lower activity. The 2,3,4-trihydroxybenzaldoxime derivative had a much lower activity than had the dihydroxybenzaldoxime derivatives. The zinc(II) analog of C uS A 02 had only a low antiproliferative activity. The ligand of C uSA 02, salicylaldoxime, resembles pyridoxal oxime, a vitamin B6 antag onist and a powerful inhibitor of pyridoxal kinase. An attempt to reduce the toxicity of C uS A 02 in vivo with pyridoxal hydrochloride led to increased toxicity. 
Introduction
We have recently shown that r/Yws-bis(salicylaldoximato)copper(II) (CuSA02; la, Z = OH, M = Cu, R = R' = R" = H) and its derivative trans-bis-(2,4-dihydroxybenzaldoximato)copper(II) (CuRES2; lb, Z = OH, M = Cu, R = R" = H, R' = OH) have a very strong antiproliferative activity against tumor cells in vitro. Both compounds were shown to totally arrest the proliferation of leukemia L1210 and Ehr lich ascites carcinoma cells in the concentration of about 5 ng/ml [!] • The antiproliferative activity is a property of the intact chelates only. The ligand part of CuSA02, salicylaldoxime, had no antiproliferative activity even in high concentrations, and free copper(II) salts had only a very limited activity [1] .
Further, it was shown that CuSA02 has strong antitumor activity against Ehrlich ascites carcinoma I in mice in vivo [2] . Because of these promising re sults, further studies on the compounds and their derivatives are warranted. Screening of new deriva tives is especially interesting, not only because it may lead to the discovery of new active compounds, but also because it may reveal possible structure-activity correlations. Such correlations may in turn be valu able in the elucidation of the mechanism of action of the compounds, and may also form the basis for a more rational search of derivatives of higher activity. Therefore, we have now synthesized some deriva tives and analogs of CuSA 02 and CuRES2, and tested them against leukemia L1210 cells in vitro. We also report here the results of some preliminary in vivo experiments on CuSAO?.
Materials and Methods

Chemicals
CuSA 02 [3] and the corresponding Zn(II) chelate (le) [4] were prepared as previously described. Com pound Id (see Table I for substituents) was prepared according to the method of Pfeiffer et al. [5] . Com pound II was prepared essentially according to the method of Dubsky and Sokol [6] . The syntheses of other compounds will be described elsewhere.
Analytical data on the compounds tested in vitro are given in Table I .
Pyridoxal hydrochloride (biochemical grade) and dimethyl sulfoxide (spectroscopical grade or scintilla tion grade) were obtained from E. Merck.
In vitro screening
Mouse L1210 leukemia cells were grown at 37 °C in Gibco's medium RPMI 1640 supplemented with 5% (v/v) of pooled human serum (Finnish Red Cross Transfusion Service), 2 m M glutamine, and 50 mg of the sodium salt of penicillin G and 50 mg of strep tomycin per litre. The cells were counted using a particle counter (Coulter Electronics, model Indus trial D). -For each test series, a confluent cell sus pension was diluted, the cells were counted, and 5 ml aliquots of the suspension were grown in tightly closed disposable culture tubes of 10 ml volume. The test substances were added as solutions or suspen sions in dimethyl sulfoxide (E. Merck) (25 pil/5 ml). Controls and solvent controls were employed. The number of cells in each tube was counted after 1 and 2 days. For each compound and concentration tested, the value of the growth ratio was calculated, where N is the number of cells in the tube containing the test substance, C is the mean number of cells in the solvent control tubes, and A is the initial value. Percentage inhibition, obtained by subtracting the value of Y from 100%, was plotted against concentration, and approximate concentra tions which inhibit growth to 50% of control growth (IC50) were determined graphically.
In vivo experiments
NMRI mice were obtained from the Department of Pharmacy of the University of Helsinki. They were housed at ordinary room temperature with a 12 h light-dark cycle and were given a standard laboratory diet and tap water ad libitum.
The detergent solution used in the pyridoxal experiment was prepared by dissolving 100 jxl of Tween 20® (polyoxyethylenesorbitan monolaurate; Ph. Eur. grade) in 100 ml of 0.9% aqueous NaCl solution.
Results and Discussion
In vitro screening of derivatives of CuSA 0 2
Most of the CuSA0 2 derivatives and analogs tested had the general formula I. Table I shows the results of screening in cell culture. Usually, four different concentrations were tested for each com pound.
The salicylaldimine analog (lc) of CuSA02 was found to have a considerable antiproliferative activi ty. During the first day, its IC5o value was as low as ca. 3-4 ^ig/ml, the 2-day value being even lower. The compound is a potential candidate for testing in vivo. The results given in Table I were obtained with a freshly prepared solution of lc. The compound is unstable in dimethyl sulfoxide, as indicated by color changes, and when the solutions are allowed to stand for several days, the antiproliferative activity is lost almost totally. The corresponding zinc chelate (Id) had a much weaker activity.
We have previously shown that the nickel(II) analog of CuSA02 has only a very low antiprolifera tive activity, while the activity of the cobalt(II) analog is almost as high as that of CuSA02 [1] . The present results indicate that the corresponding zinc(II) chelate (le) is only a weak inhibitor of tumor cell proliferation. Copper and cobalt compounds are usually more prone to redox reactions than are nickel and zinc compounds. Thus, taken together, the re sults suggest that redox reactions may have a role in the antiproliferative activity of CuSA02 and related compounds. Other explanations for the low activity of the nickel and zinc chelates cannot, however, be ruled out. For example, the low activity of the zinc chelate may at least in part be due to its very low solubility.
The 2,3-and 2,5-dihydroxybenzaldoxime deriva tives (If) and (lg) are isomers of the previously stud ied CuRES2 [1] . All of these compounds have a very high antiproliferative activity against L1210 leukemia cells. The in vitro dose-response curves of CuRES2 [7] and If rise very steeply between 3 and 5 pig/ml, just like that of CuSAO? [7] , and reach ca. 90% in hibition at about 5 pig/ml. In the case of lg, however, the rise of the curve is somewhat less steep, and higher concentrations are needed for 90% inhibition. The antiproliferative activity of the 2,3,4-trihydroxybenzaldoxime derivative (Ih) is clearly lower than that of the dihydroxybenzaldoxime derivatives studied. Even at the concentration of 20 pig/ml, only 60% inhibition was achieved with this compound.
Hodnett and coworkers have shown that certain cobalt(II) complexes of Schiff bases of salicylaldehyde and aminoalcohols have antitumor activity [8] [9] [10] . The chelate of the Schiff base of salicylaldehyde and 3-amino-l-propanol appeared to have especially good antitumor activity [8] . Also some related Schiff bases in their own right slow tumor growth [10] [11] [12] [13] [14] , The cobalt complexes reported by Hodnett et al. are structurally related to CuSA 02. Therefore, we prepared the copper(II) chelates (Ii) and (I j) of the salicylaldehyde Schiff bases of 2-amino-1-ethanol and 3-amino-l-propanol, respectively. The chelate Ik of the Schiff base formed by 2,3-dihydroxybenzaldehyde and 3-amino-l-propanol was also synthesized. All of these compounds had moder ate antiproliferative activity but were clearly less active than CuSA02.
Compound II, the copper(II) chelate of the tetradentate ligand N,N'-bis(salicylidene)ethylenediamine, was the only one of the present CuSA 02 analogs that did not have any measurable antipro liferative activity. There is at least one major differ ence between the structure of this compound and all c h .
, N o'N, the others tested. Namely, compound II cannot exist in the rram'-configuration that is typical of most CuSA 02 type compounds. This configurational re striction, caused by the structure of the ligand, may well lie behind the total lack of antiproliferative activity. We are currently engaged in the synthesis of other analogs having a similar configurational restric tion. Studies on them might reveal, whether transconfiguration about the metal ion is essential for the antiproliferative activity of CuSA02 type com pounds. This point is very interesting, because in the case of the well-known and clinically important plati num anticancer drugs, the c/s-isomers have high anti tumor activity while the trans-isomers do not show any appreciable activity [15 -17] . Hall and Waters [18] have shown that the configuration about the copper atom in II is pyramidal in the solid state. It is possible that the compound has this configuration in solution, too. Such non-planarity might also lie behind the lack of biological activity.
In vivo studies on CuSA 0 2
We have previously reported [2] experiments showing that CuSA 02 has a remarkable antitumor activity against EAC in vivo. In those experiments, some CuSA 02-treated mice were totally cured, being still alive and apparently healthy 101 days after the injection of EAC cells. Four of those mice were then used for a preliminary immunity test, the results of which are reported here. Each of the test mice (weighing 28-35 g) and each of the ten control mice (weighing 24-34 g, mean 29.7 ± 2.58 g) were given i.p. 0.18x 106 EAC cells. The mean survival time of the controls was 22.1 ± 2.2 days. Two of the cured CuSA 02-treated mice died of EAC (survival times 20 and 21 days). The other two were resistant and did not take EAC. No increase in their body weights was detected during 40 days. These very preliminary re sults are in line with those of Kimoto and coworkers [19] , who treated EAC-inoculated mice with a com bination of sodium ascorbate and the copper(II) che late of glycylglycylhistidine and found that those mice that survived over 60 days, were resistant to a new EAC inoculum. Therefore, further studies on the immunological consequences of treatment of tumors with CuSAO? and other Cu(II) compounds are strongly warranted and might give valuable infor mation on the mechanisms of tumor immunity.
The ligand of CuSA02, salicylaldoxime (III), re sembles pyridoxal oxime (IV), a well-known vitamin
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IV B6 analog and antagonist and an extremely powerful inhibitor of pyridoxal kinase [20] [21] [22] [23] . On the other hand, vitamin B6 deficiency and B6 antagonists are known to have growth inhibiting and antitumor ac tivity [24, 25] . These data, together with the finding that the side-effects of CuSAOi (acrodynia and weight loss) [2] resemble those of vitamin B6 defi ciency and of B6 antagonists [24, 26] . led us to ex plore the possible interaction of CuSA02 and the B6 vitamer pyridoxal. It was hoped that pyridoxal could be used as an antidote of CuSA 02. Thus, a preliminary study was performed, in which female NMRI mice were given i.p. either first saline and 30 minutes thereafter CuSA 02 (30 mg kg-1), or first pyridoxal hydrochloride (100 mg kg-1) and then CuSA 02 (30 mg kg-1), or first pyridoxal hydro chloride (100 mg kg_I) and then saline. The treat ments were repeated after 7 h. Appropriate vehicle controls were also employed. (For details, see the legend of Fig. 1 .) As is evident from Fig. 1 , the mice which twice received pyridoxal hydrochloride and CuSA 02, suffered a weight loss approximately equal to that of the animals which twice received saline and CuSA 02, but recovered weight more slowly than the latter. Thus, in the dosage used, pyridoxal hydro chloride did not reduce but, if anything, increased the toxicity of CuSA02. The administration of saline and pyridoxal hydrochloride did not cause any weight loss. Two of the six mice treated with pyridoxal hydrochloride and CuSAOi died (during days 3 and 4), while all mice in other groups survived to the end of the experiment (21 days).
In spite of the finding that pyridoxal did not reduce the toxicity of CuSA02, the possibility cannot be ex cluded that the mechanism of action of CuSA 02 is based on vitamin B6 antagonism. B6 antagonists are namely known, whose effects cannot be reversed by B6 vitamers [27] , Thus, further studies on the possi ble role of pyridoxal kinase inhibition in the mecha nism of action of CuSAO? type compounds are war
ranted. An experiment of the type described above but employing various different timing and dosage schedules might also be warranted.
